Drug Trial Radar · NCT06480240
A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
117
Planned (sponsor's estimate)
Start
Jun 12, 2024
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- OBI Pharma, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part trial: Part A (Dose Escalation) is designed to establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of OBI-992 (Anti-TROP2 antibody drug conjugate, anti-TROP2 monoclonal antibody-cleavable peptide linker-exatecan) as monotherapy. Part B (Cohort Expansion) is intended to further characterize the safety and preliminary clinical activity profile of the RP2D of OBI-992 in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
OBI-992Drug
OBI-992 is an antibody-drug conjugate
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability of OBI-992: incidence of adverse events, serious adverse events, and laboratory abnormalitiesTime frame: Duration of study, up to 2 years and 2 months
- Maximum tolerated dose and recommended Phase 2 dose of OBI-992Time frame: Duration of study, up to 2 years and 2 months
- Preliminary clinical activity profile - objective response rate (ORR)Time frame: Duration of study, up to 2 years and 2 months
- Preliminary clinical activity profile - clinical benefit rate (CBR)Time frame: Duration of study, up to 2 years and 2 months
- Preliminary clinical activity profile - duration of response (DOR)Time frame: Duration of study, up to 2 years and 2 months
- Preliminary clinical activity profile - disease control rate (DCR)Time frame: Duration of study, up to 2 years and 2 months
- Preliminary clinical activity profile - progression-free survivalTime frame: Duration of study, up to 2 years and 2 months
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
California Clinical Trials Medical Group (CCTMG)
Glendale, California
Scripps Green Hospital
La Jolla, California
Karmanos Cancer Institute
Detroit, Michigan
The University of Texas MD Anderson Cancer Center
Houston, Texas
NEXT Oncology
San Antonio, Texas
NEXT Virginia
Fairfax, Virginia
Taipei Tzu Chi Hospital
New Taipei City, Xindian District, Taiwan
Taipei Medical University - Shuang Ho Hospital
New Taipei City, Zhonghe District, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.